CNTX Stock Summary and Trading Ideas (Context Therapeutics | NASDAQ:CNTX)

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Context Therapeutics trades on the NASDAQ stock market under the symbol CNTX.

As of October 12, 2026, CNTX stock price was flat at $0.31 with 488,066 million shares trading.

CNTX has a beta of -0.70, meaning it tends to be less sensitive to market movements. CNTX has a correlation of 0.00 to the broad based SPY ETF.

CNTX has a market cap of $28.02 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, CNTX traded as high as $3.62 and as low as $.29.

The top ETF exchange traded funds that CNTX belongs to (by Net Assets): VTI, IWM, IWO, VTWO, VXF.

CNTX has underperformed the market in the last year with a price return of -78.2% while the SPY ETF gained +20.3%. CNTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -53.3% and -6.5%, respectively, while the SPY returned +3.3% and +1.6%, respectively.

CNTX support price is $.29 and resistance is $.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNTX shares will trade within this expected range on the day.